Fragmin for VTE in cancer patients

The licence for Fragmin (dalteparin sodium) has been extended to include use in patients with solid tumours for the treatment of symptomatic venous thromboembolism (VTE) and the prevention of recurrence.

Fragmin may now be used for up to six months with a recommended dose of 200 international units/kg once daily for the first month and 150 international units/kg daily for the proceeding months. The dose will need to be adjusted in patients with significant renal failure or chemotherapy-induced thrombocytopenia.

View Fragmin drug record

Further information: Pfizer

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more